Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Antiviral Res. 2019 May 31;168:134–145. doi: 10.1016/j.antiviral.2019.05.015

Figure 1. ONC201 has an antiviral effect on macrophages.

Figure 1.

A) Human MDM were plated in 96-well plates and infected with HIV-1 for 24 hours before incubation with doses of ONC201 or its isomer ranging from 0.03 to 30 μM. Uninfected MDM were treated with the same ONC201 and isomer dosages in parallel for comparison. At 5-day post ONC201 and isomer treatments, cell viability was determined by the MTS assays. Data were analyzed by two-way ANOVA, and results shown are the means ± SD of 3 experiments. B) At the same experimental end point as the MTS assays, supernatants were removed and the replication levels of HIV-1 were monitored by RTase activity assay. Results shown are from representative experiments performed with three different donors. Data were analyzed by two-way ANOVA: ** denotes p < 0.01, *** denotes p < 0.001, compared to the HIV-1+ONC201 isomer group of the same treatment dosage.